Innovative Medicine Initiative - Future topics

Overview of future topics in The Innovative Medicines Initiative. The calls are expected to be published sometime in November 2017 and the deadlines are expected around February and March 2018.

Link to the call

The Innovative Medicines Initiative (IMI)

IMI is a partnership between the European Union and the European pharmaceutical industry. IMI facilitates open collaboration in research to advance the development of, and accelerate patient access to, personalised medicines for the health and wellbeing of all, especially in areas of unmet medical need.

The topics

Assessment of the uniqueness of diabetic cardiomyopathy relative to other forms of heart failure using unbiased pheno-mapping approaches

Genome-environment interactions in inflammatory skin disease

The value of diagnostics to combat antimicrobial resistance by optimising antibiotic use

Mitochondrial dysfunction in neurodegeneration

Support and coordination action for the projects of the neurodegeneration area of the innovative medicines initiative

A sustainable European induced pluripotent stem cell platform

Linking digital assessment of mobility to clinical endpoints to drive regulatory acceptance and clinical practice

Human tumour microenvironment immunoprofiling

CONCEPTION – continuum of evidence from pregnancy exposures, reproductive toxicology and breastfeeding to improve outcomes now

Improving the preclinical prediction of adverse effects of pharmaceuticals on the nervous system

Translational safety biomarker pipeline (TRANSBIOLINE): enabling development and implementation of novel safety biomarkers in clinical trials and diagnosis of disease

Federated and privacy-preserving machine learning in support of drug discovery

Pilot programme on a clinical compound bank for repurposing
This programme includes the following topics:
 - Cardiovascular diseases and diabetes
 - Respiratory diseases
 - Neurodegenerative diseases
 - Rare/orphan diseases

Published Nov. 9, 2017 2:04 PM - Last modified Nov. 9, 2017 2:05 PM